
| Pair Name | Triptolide, Doxorubicin | ||
| Phytochemical Name | Triptolide (PubChem CID: 107985 ) | ||
| Anticancer drug Name | Doxorubicin (PubChem CID: 31703 ) | ||
| Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
| Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
||
| Pair Name | Triptolide, Doxorubicin | |||
| Disease Info | [ICD-11: 2B33.4] | Leukemia | Investigative | |
| Biological Phenomena | Induction-->Ferroptosis | |||
| Gene Regulation | Down-regulation | Expression | NFE2L2 | hsa4780 |
| Down-regulation | Expression | GPX4 | hsa2879 | |
| In Vitro Model | K-562 | Blast phase chronic myelogenous leukemia | Homo sapiens (Human) | CVCL_0004 |
| HL-60 | Adult acute myeloid leukemia | Homo sapiens (Human) | CVCL_0002 | |
| Result | The present study indicated that Nrf2 served a critical role in leukemia cell resistance to DOX and triptolide‑induced ferroptosis and suggested a potential strategy of combination therapy using triptolide and DOX in leukemia treatment. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Triptolide promotes ferroptosis by suppressing Nrf2 to overcome leukemia cell resistance to doxorubicin. Mol Med Rep. 2023 Jan;27(1):17. doi: 10.3892/mmr.2022.12904. | Click |